Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galera Therapeutics Inc GRTX

Healthcare Biotechnology
Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in... see more

Recent & Breaking News (OTCPK:GRTX)

Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis

GlobeNewswire October 19, 2021

Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer

GlobeNewswire October 12, 2021

Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer

GlobeNewswire September 14, 2021

Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters

GlobeNewswire September 8, 2021

Galera to Present at Three Upcoming Investor Conferences in September

GlobeNewswire September 7, 2021

Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments

GlobeNewswire August 10, 2021

Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis

GlobeNewswire June 28, 2021

Galera to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 26, 2021

Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer

GlobeNewswire May 17, 2021

Science Translational Medicine Article Shows Galera's Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors

GlobeNewswire May 12, 2021

Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments

GlobeNewswire May 11, 2021

Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference

GlobeNewswire May 5, 2021

Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer

GlobeNewswire April 28, 2021

Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments

GlobeNewswire March 11, 2021

Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

GlobeNewswire March 10, 2021

Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

GlobeNewswire November 20, 2020

Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates

GlobeNewswire November 10, 2020

Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

GlobeNewswire November 3, 2020

Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer

GlobeNewswire October 27, 2020

Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer

GlobeNewswire October 23, 2020